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Summary
Telomere dysfunction and associated fusion-breakage in the mouse encourages epithelial carcinogenesis and a more
humanized genomic profile that includes nonreciprocal translocations (NRTs). Here, array comparative genomic hybridiza-
tion was used to determine the pathogenic significance of NRTs and to determine whether telomere dysfunction also
drives amplifications and deletions of cancer-relevant loci. Compared to tumors arising in mice with intact telomeres,
tumors with telomere dysfunction possessed higher levels of genomic instability and showed numerous amplifications
and deletions in regions syntenic to human cancer hotspots. These observations suggest that telomere-based crisis
provides a mechanism of chromosomal instability, including regional amplifications and deletions, that drives carcinogene-
sis. This model provides a platform for discovery of genes responsible for the major cancers affecting aged humans.
Introduction 1999; Karanjawala et al., 2002), and diminished nonhomologous
end-joining (Karanjawala et al., 1999; Shen et al., 2000; O’Dris-
Chromosomal structural aberrations are a hallmark feature of coll et al., 2001; Sharpless et al., 2001; Karanjawala et al., 2002),
human epithelial cancers and the end product of compromised among others (DePinho, 2000; Lengauer, 2001). The analysis
of human cultured cells in crisis (Counter et al., 1992), evolvinggenome stability mechanisms. Perhaps the most prominent and
pathogenetically relevant aberrations are those that result in human colorectal cancers (Hastie et al., 1990; Chadeneau et
al., 1995; Rudolph et al., 2001), engineered telomeric doublethe regional amplification and deletion of oncogene and tumor
suppressor gene loci. Consequently, significant effort has been strand breaks in mouse embryonic stem cells (Lo et al., 2002),
and tumors arising in mice with telomere dysfunction (Chin etdevoted to elucidating the mechanisms that generate these
“chromosomal numerical aberrations” (CNAs), which clearly al., 1999; Artandi et al., 2000) has supported the view that
telomere dysfunction can serve as a potent driving force indrive would-be cancer cells toward a threshold of altered gene
functions required for malignant transformation. This threshold the production of complex chromosomal rearrangements and
aneuploidy.has been estimated to be higher in epithelial cancers relative
to neoplasms originating in mesenchymal or hematopoietic lin- Unlike humans, the laboratory mouse, Mus musculus, pos-
sesses long telomeres and shows ready activation of telomeraseeages (Armitage and Doll, 1954). Several possible mechanisms
have been proposed and experimentally validated, and include in the setting of neoplasia (Kipling and Cooke, 1990; Broccoli
et al., 1996); thus, telomere-based crisis does not appear todefects in the mitotic checkpoint machinery (Elledge, 1996; No-
jima, 1997; Wassmann and Benezra, 2001), increased oxidative take place in mouse cancer cells (Prowse and Greider, 1995).
In addition, there are significant species differences in tumorstress (Bohr et al., 1998; Olinski et al., 1998; Bohr and Dianov,
S I G N I F I C A N C E
Dissection of the molecular mechanisms underlying cancer-associated chromosomal structural aberrations, such as amplifications
and deletions, remains an important focus in the cancer field. The data of this report lend support to the thesis that telomere dysfunction
and resultant fusion-bridge-break cycles represent one mechanism that drives the numerous regional amplifications and deletions
across the cancer genome. That these chromosomal aberrations are clonal and recurrent in independent tumors suggests pathoge-
netic relevance to epithelial carcinogenesis. Importantly, many of these amplifications and deletions target regions syntenic to
cancer hotspots in human epithelial cancers, providing a system for the discovery of genes responsible for the most common human
cancers.
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spectrum associated with advancing age: aged humans develop
predominantly epithelial cancers, while mice sustain a high inci-
dence of lymphomas and soft tissue sarcoma throughout life
(DePinho, 2000). As such, these cross-species differences pro-
vided an ideal experimental framework in which to engineer
telomere-based crisis in the mouse in order to assess the impact
of crisis on the cancer process in vivo. In p53 mutant mice
lacking the telomerase RNA component (mTerc), telomere dys-
function and advancing age has been shown to result in a
marked shift in tumor spectrum toward one more typical of aged
humans: epithelial cancers of the colon, breast, and skin, among
others (Artandi et al., 2000). Significantly, these murine cancers
also present with a more classical human carcinoma cytogenetic
profile, most notably marked aneuploidy and numerous com-
plex unbalanced translocations (UBTs) (Artandi et al., 2000). In
this study, the presence of amplifications and deletions, another
hallmark and perhaps more pathogenically relevant feature of
the cancer genome, was not assessed. Along these lines, it is
worth noting that previous work in cultured cells has established
that chromosome damage and DSBs can provide a nidus for
amplification or deletion at the site of breakage (Windle et al.,
1991; Kimmel et al., 1992; Pipiras et al., 1998). As UBTs result
from the production and repair of double-stranded DNA breaks
(DSBs), we utilized array-comparative genomic hybridization
(array-CGH) to determine whether the bridge-fusion-breakage Figure 1. Late generation mTerc/,p53/ cancer genomes exhibit signifi-
cantly greater levels of genomic instability than early generationprocess that accompanies telomere dysfunction was associ-
mTerc/,p53/ tumorsated with clonal and regional alterations in gene/loci dosage
A: Histogram illustrates the frequency of BACs exhibiting copy numberand whether such numerical aberrations involve regions with
changes as determined by array-CGH. G0–G2 represents tumors from
potential relevance to the transformation process. mTerc/,p53/ and early generation mTerc/,p53/ mice. G4–G7 repre-
sents tumors from late generation mTerc/,p53/ mice.
B: Table illustrates the frequency of BACs exhibiting copy number changesResults and Discussion
as determined by array-CGH for individual tumor types.
Array-CGH assays were conducted on a collection of mam-
mary carcinomas, squamous cell carcinomas of the skin (SCC),
and colorectal cancers derived from late generation from late generation mTerc/ mice with telomere dysfunction
mTerc/,p53/ mice, as well as on tumors derived from early (Artandi et al., 2000).
generation mTerc/,p53/ mice of the same cohort. These 32 CNAs were found to be recurrent in at least one of the
studies utilized arrays of 931 mouse BACs at 3 Mb coverage three tumor types, with recurrence defined as present in at least
of the mouse genome. Late generation mTerc/,p53/ cancer 25% of the tumors examined in this study. The most prominent
genomes showed extensive focal alterations involving 20.5% and consistent change was a 5- to 6-fold amplification of distal
(SEM  3.1) of the arrayed BACs, which contrasts with more chromosome 6, observed in 8 of 15 samples representing all 3
modest CNA levels (2.5%, SEM  1.3) detected in tumors aris- tumor types. The involvement of distal chromosome 6 corre-
ing in early generation mTerc/,p53/ mice from the same sponds well with previous spectral karyotype analyses showing
cohort (p  0.004). Since epithelial carcinomas are rare in mice UBTs involving distal chromosome 6 in some late generation
with intact telomere function, it was not possible to perform a mTerc/,p53/ breast tumors and the absence of re-
precise comparison of the level of telomere-induced genomic arrangements in this region in breast tumors derived from
changes in the same cancer type. However, an examination of mTerc/ MMTV-Wnt1 p53 mutant mice (Artandi et al., 2000).
late generation mTerc/,p53/ lymphomas and osteosarcoma Amplification of this region has also been observed in viral onco-
genomes revealed a significantly greater level of chromosomal gene-induced skin cancers arising in late generation mTerc/
instability than mTerc/,p53/ lymphomas and osteosarcoma mice (D. Argilla et al., submitted). Together, these findings raise
genomes (Figure 1B), indicating that telomere dysfunction can the possibility that this locus encodes an oncogene relevant to
provoke a marked increase in chromosomal alterations indepen- the pathogenesis of many epithelial cancers or an adaptive
dent of tumor type. More directly, we also examined a small factor that enables tumorigenesis in the face of telomere dys-
collection of mammary carcinomas arising in late generation function.
mTerc/ MMTV-Wnt1 transgenic mice and found a higher level To characterize the locus on distal chromosome 6 at higher
of chromosomal instability (9.2%, SEM  3.9) relative to mam- resolution, the mouse genome sequence database was used
mary carcinomas arising in mTerc/ MMTV-Wnt1 transgenic to identify closely spaced markers spanning the region of ampli-
mice (0.4%, SEM  0.1; p 0.05) These array-CGH results are fication identified by array-CGH. Using these markers, slot blot
in line with previous spectral karyotype analyses showing a DNA analysis of the same set of mTerc/,p53/ tumors de-
limited the minimal region of involvement to a 250 kb regionmarked increase in aneuploidy and NRTs in tumors derived
150 CANCER CELL : AUGUST 2002
R E P O R T
Figure 2. Identification of the minimal amplicon
on mouse chromosome 6
The extent of the region of amplification at distal
chromosome 6 is indicated by the black bars for
13 mTerc/,p53/ tumors that contained ampli-
fications in this region. The name of the marker,
and its position on chromosome 6 (defined by
mouse genome database), are indicated in the
upper part of the figure.
located between 140.15 and 140.40 Mb on chromosome 6 the distal chromosome 6 amplification in the late generation
mTerc/,p53/ breast adenocarcinomas.(Figure 2). This region includes six known or predicted genes
with no obvious links to DNA repair responses, recombination, In addition to amplification of distal chromosome 6, array-
CGH analyses of the mTerc/,p53/ carcinomas revealed nu-alternative lengthening of telomeres (ALT), or other telomere-
relevant pathways (note that Rad52 falls outside of the minimal merous recurrent amplifications or deletions affecting previously
recognized cytogenetic hotspots in human cancers (Tables 1–3amplicon boundary). K-Ras is contained within the amplicon
and this gene, while clearly important in the pathogenesis of a and Figure 3). Significantly, these CNAs were not detected in
numerous tumor types derived from mTerc/,p53/ mice, andbroad spectrum of epithelial cancers, is not known to be in-
volved in modulating the cellular response to telomere dysfunc- no recurrent loci were identified in mTerc/,p53/ tumors (data
not shown). In the late generation mTerc/,p53/ tumors, ation. It is conceivable that K-Ras might regulate the expression
or activity of genes involved in this adaptive response, since number of CNAs were noteworthy when compared to the data-
base of CNAs derived from human tumors. For each recurrentK-, H-, and N-Ras have been shown to enhance the expression
of a number of DNA processing enzymes (Zuber et al., 2000). CNA in the mouse, the largest single occurrence was mapped
onto the human genome using the NCBI mouse-human homol-It is noteworthy that amplification of distal chromosome 6, in-
cluding K-ras, is not observed in MMTV-Wnt1 late generation ogy database, and the corresponding human chromosomal re-
gion analyzed for the presence of known cancer hotspots and/mTerc/ breast cancers. In these tumors, Wnt1 acts as a domi-
nant oncogene, and activation of the Wnt signaling pathway or breakpoints. In Tables 1–3, the neighboring genes define the
extent of the human chromosome that is homologous to thewas recently shown to be sufficient to replace receptor-tyrosine-
kinase/Ras signaling in C. elegans vulval development (Gleason CNA observed in the mouse.
In the mTerc/,p53/ breast adenocarcinomas, eight re-et al., 2002). This genetic evidence provides a rational explana-
tion for the lack of K-ras amplifications in the Wnt1-driven tu- current CNAs were identified. The chromosome 11 amplicon,
present in four of seven breast tumors, corresponds to humanmors and supports the hypothesis that K-ras is the target of
Table 1. Recurrent CNAs in mTerc/,p53/ breast cancers (n  7)
Frequency of Frequency of Human Neighboring Breast tumor
Mouse BAC1 Chromosome Location (cM) amplification deletion synteny genes number
D1MIT369 1 73 3 0 1q31 PTPRC, MYOG 2,6,7
D5MIT132 5 29 0 3 4p15 CD38 1,3,4
D6MIT295 6 73.6 3 0 12p12 KRAS2, BCAT1, BHLHB3 1,2,5
D6MIT15 6 74 3 0 12p12 KRAS2, BCAT1, BHLHB3 1,2,5
D7MIT46 7 69 3 0 11p15 LSP1, IGF2 1,2,6
D11MIT362 11 75 4 0 17q23-25 GRB2, MAFG 1,2,3,5
D13MIT312 13 44 0 3 5q13-21 CRTL1, PCSK1 2,3,4
D17MIT87 17 33.8 0 4 19p13; 16pter CLPP; SULT1A2 1,2,3,5
1Mouse BAC indicates the minimal common region altered in all recurrences of each CNA identified.
CANCER CELL : AUGUST 2002 151
R E P O R T
Table 2. Recurrent CNAs in mTerc/,p53/ SCCs (n  4)
Frequency of Frequency of Human Neighboring SCC tumor
Mouse BAC1 Chromosome Location (cM) amplification deletion synteny genes number
D5MIT155 5 53 3 0 4q13-20 GKP2, SCYB9 2,3,4
D6MIT295 6 73.6 3 0 12p12 KRAS2, BCAT1, BHLHB3 2,3,4
D8MIT45 8 40 4 0 16q12-13; 18q23 ADCY7, CBLN1 1,2,3,4
D10MIT218 10 29 3 0 6q21 ROS1, AIM1 1,3,4
D11MIT362 11 75 3 0 17q23-25 GRB2, MAFFG 2,3,4
D13MIT279 13 36 4 0 9q22 FANCC, PTCH 1,2,3,4
1Mouse BAC indicates the minimal common region altered in all recurrences of each CNA identified.
17q24-25—a region of amplification reported previously in 10% specific to SCCs, three CNAs were syntenic to cancer hotspots
at human chromosomes 4q, 9q, and 16q that were reportedto 67% of human breast tumors (Orsetti et al., 1999; Larramendy
et al., 2000). The focal deletion on chromosome 5, detected in previously in human SCC by conventional cytogenetic analyses
(Atkin and Fox, 1992; Worsham et al., 1993). In light of thethree of seven breast tumors, bears synteni to human 4p14-15,
which sustains deletions in 16% to 39% of human breast cancer proposed connection between breakage and amplification or
deletion (Windle et al., 1991; Kimmel et al., 1992), it is noteworthycases (Orsetti et al., 1999; Richard et al., 2000). Of particular
interest is the chromosome 1 amplification, observed in three that these human cancer hotspots correspond to breakpoints
in human SCC translocations (Atkin and Fox, 1992; Worshamof seven breast tumors, and which corresponds to human 1q31,
a region amplified in 26% to 89% of human breast carcinomas et al., 1993).
In four late generation mTerc/p53/ colon cancers exam-(Loveday et al., 1999; Larramendy et al., 2000). In a recent
human breast cancer study correlating cytogenetics and telo- ined, 13 recurrent CNAs (present in two of four samples) were
identified, and four bear synteni to loci (11p15, 3p21, 8q22, andmerase activity, 25% of the tumors were found to lack telo-
merase activity, and this parameter correlated with amplification 9q31) known to experience copy number changes in human
colon carcinomas (Table 3 and Figure 1A). Amplification of chro-of 1q31 (Loveday et al., 1999). Also detected in multiple
mTerc/,p53/ breast tumors was an amplification corre- mosome 7 in a region syntenic to human 11p15 was identified in
three of four mouse colon cancers. A number of genes encodingsponding to human 11p15 and deletions syntenic to human
5q13-21 and 19p13. Deletion or loss of heterozygosity at 5q13- mucins are found in this region of 11p15, including MUC2, which
is overexpressed in metastatic colon cancers (Jang et al., 2002).21 or 19p13 has been reported in ovarian carcinomas (Aman
et al., 1993; Jenkins et al., 1993; Kiechle-Schwarz et al., 1995; Amplification of chromosome 9 with synteni to human 3p21
was observed in three of four mouse colon tumors studied.Wang et al., 2001), and 5q13 is frequently deleted in myeloid
neoplasias (Fairman et al., 1996; Gogineni et al., 1996; Castro Breakpoints in human 3p21 have been identified in metastatic
colon cancers (Gagos et al., 1995), and overexpression of theet al., 1998, 2000). These data suggest several areas of common
amplification and deletion between telomerase deficient murine CDCP1 gene, which is located at 3p21 also has been observed
in colorectal cancers (Scherl-Mostageer et al., 2001). The mouseand human spontaneous breast tumors.
In the skin carcinomas, six recurrent CNAs (defined as pres- chromosome 15 deletion in two of four mouse colon tumors
corresponds to a deletion at human 8q22 which appears toent in three of four samples) were identified (Table 2 and Figure
1A). Two of these, the amplifications on distal chromosome 6 predispose to cancer and provide an initiating event in a subset
of human colon adenocarcinomas (Shabtai et al., 1988). In addi-(K-Ras locus) and distal chromosome 11, were also present in
the mouse breast cancers. Of the remaining four that were tion to known hotspots for colon cancers, amplification or dele-
Table 3. Recurrent CNAs in mTerc/,p53/ colon cancers (n  4)
Frequency of Frequency of Human Neighboring Colon tumor
Mouse BAC1 Chromosome Location (cM) amplification deletion synteny genes number
D1MIT227 1 81.6 3 0 1q25 SOAT1, XPR1 1,2,4
D4MIT55 4 19.6 3 0 9q33-34 TGFBR1 1,2,4
D4MIT242 4 24.5 0 3 9q31 Thioredoxin1, KLF4 1,2,4
D6MIT294 6 73.4 2 0 12p11-p12 KRAS2, BCAT1, BHLHB3 1,2
D7MIT280 7 51.5 3 0 11p15.1-15.5 HRAS, RRAS2, MRV1 1,2,4
D8MIT92 8 73.2 3 0 10p12 NRP (VEGF165R) 1,2,4
D9MIT93 9 27.0 3 0 11q23 APOA1; N-CAM 1,3,4
D9MIT280 9 67.0 3 0 3p21.3-21.2 TGFBR2, CDCP1 1,3,4
D15MIT251 15 13.6 0 2 8q22-23 SYNDECAN2, FZH6 1,2
D16MIT143 16 10.8 0 3 22q11 BID 1,2,4
D17MIT113 17 6.5 4 0 6q25-27 MEKK4 1,2,3,4
D18MIT2 18 37.0 3 0 18p11.2 MC2R, ACTHR 1,2,3
DXMIT56 X 5.7 3 0 Xp11 PCTK1, UBE1X 1,3,4
1Mouse BAC indicates the minimal common region altered in all recurrences of each CNA identified.
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Figure 3. Chromosomal alterations in tumors of
mTerc/,p53/ mice are homologous to hu-
man cancer hotspots
Chromosomal locations of CNAs detected by
array-CGH in breast (blue), skin (green), and co-
lon (red) carcinomas in mTerc/,p53/ mice.
Gains are indicated by lines to the right of the
chromosome ideograms, and losses are indi-
cated by lines to the left. Numbers and arrows
indicate the frequency with which the homolo-
gous region of a particular CNA was affected in
the corresponding human tumor.
tion of mouse chromosomes in regions that contain potential incidence of CNAs in two viral oncogenesis models, despite
telomere dysfunction, presumably related in part to the capacitycancer-relevant genes was also observed. The gut-enriched
of these viral oncoproteins to directly commandeer many can-Kruppel-like factor (KLF4) is located in a region of mouse chro-
cer-relevant pathways (D. Argilla et al., submitted). Direct com-mosome 4 syntenic to human chromosome 9q31 and deleted
parison of the extent of genomic instability in breast tumorsin three of four colon tumors. Expression of KLF4 inhibits prolif-
derived from MMTV-Wnt1, mTerc/ (9.2%, SEM  3.9) anderation in the gut, suggesting that loss of this gene might pro-
mTerc/,p53/ (20.5%, SEM  3.1) mice supports the notionmote colon cancer (Shie et al., 2000; Chen et al., 2001; Dang
that the presence of a dominantly acting oncogene reduces theet al., 2001). The recent finding of the related KLF6 protein as
necessity for telomere-dysfunction induced genomic instabilitya prostate cancer tumor suppressor in humans adds signifi-
in oncogenesis. With data reported here, we conclude that telo-cance to our observations (Narla et al., 2001). As was the case
mere dysfunction and its associated fusion-breakage processfor breast tumors, these data show that the increased epithelial
is a major mechanism driving the accumulation of CNAs thatcarcinogenesis induced in skin and colon by telomere instability
alter the dose of cancer-relevant genes. As the already consider-is driven by a spectrum of amplifications and deletions reminis-
able power of array-CGH will further increase with more densecent of those seen in the corresponding human carcinomas.
coverage of the genome, this mouse model of epithelial carcino-These array-CGH data demonstrate clonal selection of
genesis should provide a robust platform for discovery of genesCNAs within a tumor cell population, recurrence of these CNAs
responsible for the major cancers affecting the aging humanin independently derived tumors of similar and different cancer
population.types, and correspondence to known cytogenetic hotspots in
human cancers. On this basis, we conclude that telomere dys- Experimental procedures
function engenders regional CNAs that drive epithelial carcino-
Generation of mice and tumor analysisgenesis in this mouse model. The identification of chromosomal
Double heterozygous mice (mTerc/,p53/) were generated from matingsalterations in the mouse that mirror alterations identified in hu-
between multiple pairs of mTerc/ mice and p53/ mice (Jackson Labs).man SCC, breast cancer, and colon cancer is striking and lends
Both strains are of mixed genetic background, primarily 129SV and C57Bl/6.
further support to the hypothesis that telomere-based crisis These mice were intercrossed to generate G1 mTerc/,p53/ mice; G1
and associated fusion-breakage not only drives age-dependent mTerc/,p53/ intercrosses yielded G2 mTerc/,p53/ mice and so on
until G8. We used randomized cousin mating schemes to maintain geneticepithelial carcinogenesis, but is also a major force underlying
heterogeneity and prevent the generation of substrains (Artandi et al., 2000).the complex chromosomal changes present in such cancer ge-
nomes in human carcinoma. That CNAs result from telomere DNA isolation
dysfunction and contribute to tumorigenesis is supported by a Genomic DNA was isolated from tumors or normal tissue using the PURE-
markedly reduced number of rearrangements (Artandi et al., GENE DNA isolation kit (Gentra Systems) according to manufacturer’s proto-
col. 5 g of gDNA was digested with EcoRI, extracted with phenol:chloro-2000; Lu et al., 2001) and CNAs (Hodgson et al., 2001) in tumors
form, ethanol precipitated, and resuspended in sterile water prior to labeling.arising in cancer-prone mice with intact telomere function (Lu
et al., 2001), including early generation mTerc/,p53/ mice Labeling and hybridization to arrays
from the same cohort as the late generation mTerc/,p53/ Array-CGH experiments were performed with SpectralChip arrays (Spectral
Genomics) according to the manufacturer’s protocol. These arrays covermice studied herein. Additional support derives from the lower
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der(16)t(?13;16)(?q13or14;q22) in a squamous cell carcinoma of the skinthe mouse genome at a density of approximately 3 Mb and comprise 976
and larynx. Cancer Genet. Cytogenet. 58, 198–200.mapped mouse BACs from the RPCI11 BAC library. 1 g of tumor and
normal genomic DNA was labeled with Cy3-dCTP or Cy5-dCTP (Amersham Bohr, V.A., and Dianov, G.L. (1999). Oxidative DNA damage processing in
Pharmacia Biotech). Fluor-reversal experiments were performed in all cases. nuclear and mitochondrial DNA. Biochimie 81, 155–160.
Hybridizations were performed in sealed chambers for 20 hr at 60C. After
Bohr, V., Anson, R.M., Mazur, S., and Dianov, G. (1998). Oxidative DNAhybridization, slides were rinsed in 2 SSC, 0.5% SDS at room temperature,
damage processing and changes with aging. Toxicol. Lett. 102–103, 47–52.washed for 40 min in 2 SSC, 0.5% SDS at 65C, washed for 10 min in
0.2 SSC at 65C, and washed for 1 min in 0.2 SSC at 2C. Slides were Broccoli, D., Godley, L.A., Donehower, L.A., Varmus, H.E., and de Lange, T.
then air dried by centrifugation prior to imaging. (1996). Telomerase activation in mouse mammary tumors: lack of detectable
telomere shortening and evidence for regulation of telomerase RNA with cell
Image and data analysis proliferation. Mol. Cell. Biol. 16, 3765–3772.
16-bit TIF images were collected using an Axon 4000B scanner, and pro-
Castro, P.D., Fairman, J., and Nagarajan, L. (1998). The unexplored 5q13cessed initially using GenePix Pro. Subsequently, custom software was
locus: a role in hematopoietic malignancies. Leuk. Lymphoma 30, 443–448.utilized to exclude spots that demonstrated low signal/noise ratios or poor
spot morphology. Data were normalized to the ratio of medians of Cy3 and Castro, P.D., Liang, J.C., and Nagarajan, L. (2000). Deletions of chromosome
Cy5, and the normalized values converted to log base 2 ratios to weight 5q13.3 and 17p loci cooperate in myeloid neoplasms. Blood 95, 2138–2143.
gains and losses equally. Dye swap experiments were merged to calculate
Chadeneau, C., Hay, K., Hirte, H.W., Gallinger, S., and Bacchetti, S. (1995).the mean and standard deviation for each BAC. The threshold for defining
Telomerase activity associated with acquisition of malignancy in humana CNA was based on the distribution of log ratios in self-self hybridizations.
colorectal cancer. Cancer Res. 55, 2533–2536.Regions were scored as significantly increased/decreased if the CGH ratio
was 4 standard deviations above/below the mean ( 0.35, log base 2). Chen, X., Johns, D.C., Geiman, D.E., Marban, E., Dang, D.T., Hamlin, G.,
Sun, R., and Yang, V.W. (2001). Kruppel-like factor 4 (gut-enriched Kruppel-
Slot blot analysis of genomic DNA like factor) inhibits cell proliferation by blocking G1/S progression of the cell
DNA concentrations were determined by UV absorbance spectroscopy, cycle. J. Biol. Chem. 276, 30423–30428.
diluted to 5 g/ml in 0.4N NaOH, 10 mM EDTA (pH 8.0) and boiled for 5
Chin, L., Artandi, S.E., Shen, Q., Tam, A., Lee, S.L., Gottlieb, G.J., Greider,min before blotting. Slot blots (Schleicher & Schuell, Inc.) were prepared
C.W., and DePinho, R.A. (1999). p53 deficiency rescues the adverse effects
according to the manufacturer’s recommendations on Hybond-N mem-
of telomere loss and cooperates with telomere dysfunction to accelerate
branes (Amersham Pharmacia Biotech) and hybridized with 32-P random carcinogenesis. Cell 97, 527–538.
prime labeled probes for the indicated markers or genes. Membranes were
Counter, C.M., Avilion, A.A., LeFeuvre, C.E., Stewart, N.G., Greider, C.W.,washed at 65C in 2 SSC, 0.1% SDS for 15 min., 0.5 SSC, 0.1% SDS
Harley, C.B., and Bacchetti, S. (1992). Telomere shortening associated withfor 15 min., 0.25 SSC, 0.1% SDS for 15 min. Signal intensities were
chromosome instability is arrested in immortal cells which express telo-determined on a Fujifilm FLA-2000 phosphorimager using ImageGauge 3.3
merase activity. EMBO J. 11, 1921–1929.software. Background subtractions were performed and values were normal-
ized relative to markers for which no CNAs were observed in the tumors Dang, D.T., Mahatan, C.S., Dang, L.H., Agboola, I.A., and Yang, V.W. (2001).
studied. Expression of the gut-enriched Kruppel-like factor (Kruppel-like factor 4)
gene in the human colon cancer cell line RKO is dependent on CDX2.
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